Gene therapy through an innovative adeno-associated virus (AAV)-based technology platform. Approval of HEMGENIX, our gene therapy for hemophilia B, represents a major milestone in the field of genomic medicine. Advancing a clinical program in Huntington’s disease (AMT-130) along with multiple clinical programs in rare diseases, including SOD-1 ALS, temporal lobe epilepsy and Fabry’s disease.

*Led legal function of publicly traded (Nasdaq/OTC: ONCR) biotechnology company focused on RNA-based therapeutics to treat cancer patients. Responsible for general corporate matters, including securities compliance, strategic transactions, corporate governance and fiduciary matters.*Led company through culmination of strategic alternatives review and corporate wind down process, including sale of intellectual property and resolution of outstanding liabilities.*Corporate secretary with responsibility for books and records maintenance with frequent interactions with board of directors and other stakeholders on corporate affairs.*Frequently collaborated with business development team in support of intellectual property licensing, partnership and collaboration opportunities; human resources team with respect to employment law, employee training programs and personnel matters; and investor relations and corporate affairs, including press activity, website management, corporate communications and related disclosure and compliance considerations.

Strategic Transactions Group - Securities, Capital Markets, Public Companies and Corporate Governance.

Corporate Department - Securities, Capital Markets, Public Companies and Corporate Governance.